It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Validating a High-Throughput iPSC-Derived DRG Electrophysiology Platform
Translational Relevance of iPSC-Derived Sensory Neurons
To address the critical need for scalable and human-relevant models in pain research, we validated an automated patch clamp platform using RealDRGx™ iPSC-derived sensory neurons, which offer native-like electrophysiological behaviour and compatibility with high-throughput workflows. This platform is ideal for studying sensory neuron excitability and screening novel pharmacological agents targeting inflammatory and neuropathic pain. Dorsal root ganglion (DRG) neurons are key mediators of nociceptive signalling and are central to the development of analgesics. However, traditional primary neuron models are limited by variability and low throughput. Our iPSC-derived DRG system enables a reproducible, scalable alternative for preclinical screening.
Six-Week Electrophysiological Profiling of RealDRGx™ Neurons
RealDRGx™ neurons consistently met quality control benchmarks, demonstrating high assay success rates and stable biophysical properties from week 3 onward—supporting confident integration into screening cascades. Over six weeks of maturation, we monitored:
Our assay was developed on the SyncroPatch 384i platform, enabling efficient, automated whole-cell recordings. The screenshot highlights consistent seal formation and current traces across the plate, confirming the platform’s suitability for scalable iPSC-derived DRG screening.
Consistent Low Series Resistance
Series resistance remained stable and below the 20 MΩ QC threshold throughout six weeks of iPSC-derived DRG neuron maturation. This ensures high-quality recordings and accurate voltage control- essential for precise ion channel characterization.
Reliable Seal Formation
Seal resistance exceeded 200 MΩ in over 85% of recorded cells each week, supporting robust electrophysiology access and high success rates. This consistency enables confident data generation throughout your discovery campaign.
Pharmacological Sensitivity Across Ion Channel Classes
Studies confirmed that RealDRGx™ sensory neurons express key voltage- and ligand-gated ion channels and respond reliably to standard tool compounds, supporting their use in pharmacological screening workflows. These results confirm functional expression and compound-responsiveness across targets relevant to pain signalling.
Figure 1: Functional Potassium Channel Expression and Pharmacological Modulation in iPSC-Derived DRG Neurons RealDRGx™ sensory neurons demonstrate robust and sustained expression of functional voltage-gated potassium (Kv) channels, with over 90% of cell exhibiting Kv currents consistently from week 1 through week 6 (left). Cumulative current traces (right) show dose-dependent inhibition of Kv-mediated outward currents following application of 4-aminopyridine (4-AP), confirming pharmacological responsiveness and supporting their utility in ion channel screening workflows.
Figure 2: Sustained Sodium Channel Expression and TTX-Mediated Inhibition in iPSC-Drived DRG Neurons iPSC-derived DRG neurons exhibited stable expression of voltage-gated sodium (Nav) channels, with over 90% of cells showing functional sodium currents across 6 weeks (left). Representative current traces (right) illustrate dose-dependent inhibition of sodium currents by tetrodotoxin (TTX), confirming pharmacological responsiveness and functional Nav channel activity in the model system.
Electrophysiology Excitability and Neuronal Firing
RealDRGx™ neurons exhibited increasing excitability over time, including spontaneous and evoked firing that was sensitive to sodium channel blockade—highlighting their functional maturity and suitability for screening. Key electrophysiological features included:
Resting membrane potential (RMP): Averaged between −40 to −50 mV
Spontaneous firing: Frequency increased over the maturation period
Evoked firing: Reliable responses to current injection from 0 to 200 pA
TTX sensitivity: Clear inhibition of firing at nanomolar concentrations
Progressive excitability: Enhanced firing behaviour from week 1 to 6
Progressive Increase in Evoked Firing Capacity
The percentage of DRG neurons capable of firing in response to depolarizing current injection increased over time, reaching over 90% by week 3, demonstrating functional excitability and assay readiness for evaluating neuronal firing modulation.
TTX-Sensitive Action Potential Firing
Representative voltage traces show evoked action potentials under control conditions and following application of 500 nM TTX. The clear inhibition confirms functional sodium channel activity and the platform’s suitability for screening excitability-modulating compounds.
A Validated, Scalable Platform for Ion Channel-Targeting Pain Drug Discovery